4D Molecular Therapeutics, Inc.
FDMTHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, 4D Molecular Therapeutics, Inc. (FDMT) is listed under Biotechnology. With a market capitalization of $596.6M, it sits in small-cap territory. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Market Cap
$596.6M
Beta
2.74
P/E (TTM)
—
P/E (Fwd)
-2.64
EPS (TTM)
$-2.63
EPS (Fwd)
$-4.09
ROE
-43.3%
ROA
-25.1%
Cash
$361.3M
Total Debt
$39.2M
Free CF
-$90.8M
52W Change
-12.0%
Annual Financials
Cash vs Debt
Where FDMT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, FDMT finished 8.19% above its 150-day moving average ($11.36) and 15.18% above its 200-day moving average ($10.67). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FDMT overbought or oversold?
At the October 20, 2026 close, FDMT's RSI(14) was 29.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $361.3M in cash comfortably exceeding the $39.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$90.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -43.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $3.1M (2022) to $85.2M (2025), reflecting a 2623% increase over the period.
With a beta above 1.5, FDMT tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, FDMT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for 4D Molecular Therapeutics, Inc. and its sector.